CliffBio
small molecule

OXCARBAZEPINE

OXCARBAZEPINE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameOXCARBAZEPINE
Active ingredientOXCARBAZEPINE
Strength600MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2023
Marketing statusRX

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.